References
- Doroshow J. Biochemical mechanisms of anthracylcine cardiac toxicity. In: Muggia FM, Green MD, Speyer JL, (eds) Cancer treatment and the heart 1992. Baltimore: John Hopkins University Press. 1992: 124-125.
- Pihkala J, Sariola H, Saarinen UM. Myocardial function and post mortem myocardial histology in children given anthracycline therapy for cancer. Pediatr Hematol Oncol 1994; 11 (3): 259–269.
- Casper ES, Gaynor JJ, Hajdu SI, et al. A prospective randomised trial of adjuvant chemotherapy with bolus versus continuous infusion of doxorubicin in patients with high-grade extremity soft tissue sarcoma and an analysis of prognostic factors. Cancer 1991;68 (6): 1221–1229.
- Bhayana V, Henderson AR. Biochemical markers of myocardial damage. Clin Biochem 1995; 28: 1–29.
- Collinson PO, Stubb PJ. Are troponins confusing? Heart 2003; 89: 1285-1287.
- Clark SJ, Newland P, Yoxall CW, Subhedar NV. Neonatal levels of cardiac troponin T with and without respira-tory distress. Arch Dis Childhood 2004;89: F348–F352.
- Kismet E, Varan A, Ayabakan C, Alehan D, Portakal 0, Buyukpamukcu M. Serum troponin T levels and echocardio-graphic evaluation in children treated with doxorubicin. Pediatr Blood Cancer 2004; 42: 220–224.
- Lipshultz SE, Rifai N, SalIan SE, et al. Predictive value of cardiac troponin T in paediatric patients at risk for myocar-dial injury. Circulation 1997; 96: 2641–2688.
- Fink FM, Genser N, Fink C, et al. Cardiac troponin T and creatine kinase MB mass concentration in children receiv-ing anthracycline chemotherapy. Medical Pediatric Oncology 1995; 25: 185–189.
- Anonymous. Troponin T STAT data sheet. Roche Diagnostics GmbH, Mannheim, Germany. January1999.
- Lipshultz SE, Rifai N, Dalton V, et al. The effect of dexrazone on myocardial injury in doxorubicin treated children with acute lymphoblastic leukaemia. N Engl J Med 2004; 351: 145–153.
- Matthew P, Suarez W, Kip K, et al. Is there a potential role for serum cardiac troponin I as a marker for myocardial dysfunction in paediatric patients receiving anthracylcine based therapy? A pilot study. Cancer Invest 2001; 19: 352–359.
- Auner HW, Tinchon C, Linkesch W, et al. Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adult with hematological malignancies. Ann Hematol 2003; 82: 218–222.
- Cardinale D, Sandri MT, Colombo A, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high dose chemotherapy. Circulation 2004; 109: 2749–2754.